Chabner Colloquium


November 18, 2019
Boston, Massachusetts USA

Bruce Chabner

Founded by Dr. Bruce A. Chabner, this annual symposium, presented in joint partnership with the Massachusetts General Hospital Cancer Center, encourages dialogue among experts on topics that bring cancer biology to clinical application. The Chabner Colloquium is an intensive and thoughtful look at the potential for rational, collaborative drug development, tapping into the resources of government, pharmaceutical and biotech companies, and globally statured cancer centers of excellence.

Focusing on new targets and their interventions; strategies for profiling and selection of patients
for targeted drug trials; and biomarkers and animal models to guide clinical development, the entire drug development process is represented. The Chabner Colloquium provides a dialogue that influences trial design, hastens cancer drug development, and, long-term, will rationalize and lend efficiency to the practice of oncology.

Bruce Chabner



New Insights into DNA Repair and Drug Response

Targeting the ATR Kinase in Cancer Therapy

PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer

Assessing DNA Repair in Clinical Trials

Targets That Defy Effective Therapy

Developing Therapies for Ras-driven Cancers

Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?

Intergenic Fusions in Advanced HR+ Breast Cancer

Promising Drug-antibody Conjugates and Cell Death Pathway Inhibitors

Genomic and Functional Characterization of Patient Derived Xenograft Models of Small Cell Lung Cancer

Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative

PARP in Breast Cancer

Junior Faculty Forum

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Financial Toxicity of Cancer

Improving Therapy for EGFR-Mutant Lung Cancers